Review



cd14 microbeads miltenyi biotec  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Miltenyi Biotec cd14 microbeads miltenyi biotec
    Cd14 Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/10__1016_slash_j__isci__2026__116736-639-174-176
    Average 94 stars, based on 23 article reviews
    cd14 microbeads miltenyi biotec - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Purification:

    Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
    Article Snippet: .. CD1c + (BDCA-1 + ) and CD141 + (BDCA-3 + ) myeloid DCs were purified from CD14-negative PBMCs using MACS isolation kits (#130-119-475, Miltenyi Biotec) or magnetic MicroBeads (#130-090-512, Miltenyi Biotech), respectively. ..

    Magnetic Cell Separation:

    Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
    Article Snippet: .. CD1c + (BDCA-1 + ) and CD141 + (BDCA-3 + ) myeloid DCs were purified from CD14-negative PBMCs using MACS isolation kits (#130-119-475, Miltenyi Biotec) or magnetic MicroBeads (#130-090-512, Miltenyi Biotech), respectively. ..

    Isolation:

    Article Title: PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
    Article Snippet: .. CD1c + (BDCA-1 + ) and CD141 + (BDCA-3 + ) myeloid DCs were purified from CD14-negative PBMCs using MACS isolation kits (#130-119-475, Miltenyi Biotec) or magnetic MicroBeads (#130-090-512, Miltenyi Biotech), respectively. ..

    Article Title: Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
    Article Snippet: NK cells were isolated from freshly isolated PBMCs using the NK-cell enrichment kit (Stem Cell Technologies) ( 70 ). .. Purity of isolated NK cells (95–99% CD3 − CD56 + ) was determined by flow cytometry using PerCP/Cy5.5-conjugated anti-CD3 (Biolegend) and PC7-conjugated anti-CD56 (Beckman Coulter) antibodies. mDCs were isolated from the same PBMCs as NK cells using the CD1c (BDCA-1) and DC-isolation kit (Miltenyi). ..

    Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
    Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC fraction was concentrated by centrifugation and resuspended in phosphate-buffered saline/EDTA (Miltenyi) containing 0.5% human albumin to obtain a cell suspension at volume desired for clinical administration (according to tumor diameter, up to maximum 4 mL). ..

    Article Title: Human dendritic cells activated with MV130 induce Th1, Th17 and IL‐10 responses via RIPK2 and MyD88 signalling pathways
    Article Snippet: .. Naïve CD4 + T cells, total DC fraction, enriched fractions of mDCs and pDCs were isolated with “Naïve CD4 + T Cell”, “Blood DCs II”, CD1c (BDCA‐1) + and CD304 (BDCA‐4/Neuropilin‐1) Isolation Kits (Miltenyi‐Biotec), respectively. ..

    Selection:

    Article Title: Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
    Article Snippet: .. Briefly, patients underwent a leukapheresis and next, CD14 + and CD19 + cells were depleted using CliniMACS ® CD14 reagent and CliniMACS ® CD19 reagent, followed by positive selection of CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC using CliniMACS ® CD1c (BDCA-1)-biotin, CliniMACS ® Anti-Biotin Reagent and CliniMACS ® CD141 (BDCA-3) Microbeads (all Miltenyi Biotec) on the immunomagnetic CliniMACS Prodigy ® system (Miltenyi Biotec). ..

    Flow Cytometry:

    Article Title: Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation
    Article Snippet: NK cells were isolated from freshly isolated PBMCs using the NK-cell enrichment kit (Stem Cell Technologies) ( 70 ). .. Purity of isolated NK cells (95–99% CD3 − CD56 + ) was determined by flow cytometry using PerCP/Cy5.5-conjugated anti-CD3 (Biolegend) and PC7-conjugated anti-CD56 (Beckman Coulter) antibodies. mDCs were isolated from the same PBMCs as NK cells using the CD1c (BDCA-1) and DC-isolation kit (Miltenyi). ..

    Staining:

    Article Title: HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa.
    Article Snippet: Background: The Human T-cell Leukemia Virus type 1 (HTLV-1) is the causative agent of several inflammatory diseases, including HTLV-1-associated inflammatory myopathies (HAIM).. Little is known about the virological and immunological characteristics of this viral disease.. Objectives: To characterize the histological and virological features of HAIM patients, in order to better understand the pathogenetic mechanisms and unravel new biological markers of this disease.

    Ubiquitin Proteomics:

    Article Title: HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa.
    Article Snippet: Background: The Human T-cell Leukemia Virus type 1 (HTLV-1) is the causative agent of several inflammatory diseases, including HTLV-1-associated inflammatory myopathies (HAIM).. Little is known about the virological and immunological characteristics of this viral disease.. Objectives: To characterize the histological and virological features of HAIM patients, in order to better understand the pathogenetic mechanisms and unravel new biological markers of this disease.

    Centrifugation:

    Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
    Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC fraction was concentrated by centrifugation and resuspended in phosphate-buffered saline/EDTA (Miltenyi) containing 0.5% human albumin to obtain a cell suspension at volume desired for clinical administration (according to tumor diameter, up to maximum 4 mL). ..

    Saline:

    Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
    Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC fraction was concentrated by centrifugation and resuspended in phosphate-buffered saline/EDTA (Miltenyi) containing 0.5% human albumin to obtain a cell suspension at volume desired for clinical administration (according to tumor diameter, up to maximum 4 mL). ..

    Suspension:

    Article Title: Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
    Article Snippet: First, CD14 + and CD19 + cells were depleted with the CliniMACS CD14 and CD19 reagents followed by a positive selection of CD1c (BDCA-1) + myDC and CD141 (BDCA-3) + myDC by using CliniMACS CD1c (BDCA-1)-biotin microbeads, CliniMACS CD141 (BDCA-3)-biotin microbeads and CliniMACS Anti-Biotin Reagent (Miltenyi) using the CliniMACS Prodigy platform (Miltenyi Biotec, Bergisch Gladbach, Germany). .. The isolated CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC fraction was concentrated by centrifugation and resuspended in phosphate-buffered saline/EDTA (Miltenyi) containing 0.5% human albumin to obtain a cell suspension at volume desired for clinical administration (according to tumor diameter, up to maximum 4 mL). ..



    Similar Products

    94
    Miltenyi Biotec cd14 microbeads miltenyi biotec
    Cd14 Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/10__1016_slash_j__isci__2026__116736-639-174-176
    Average 94 stars, based on 1 article reviews
    cd14 microbeads miltenyi biotec - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec dc2s
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Dc2s, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)+Antibody%2C+anti-human/pmc13336304-91-12-16
    Average 95 stars, based on 1 article reviews
    dc2s - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd1c isolation kit
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Cd1c Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pmc13336304-47-12-16
    Average 94 stars, based on 1 article reviews
    cd1c isolation kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human miltenyi biotec
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Human Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pm41997138-350-266-267
    Average 94 stars, based on 1 article reviews
    human miltenyi biotec - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec anti human cd1c bdca1
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Anti Human Cd1c Bdca1, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)+Antibody%2C+anti-human/pm41707448-99-118-125
    Average 95 stars, based on 1 article reviews
    anti human cd1c bdca1 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec miltenyi biotech cd1c
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Miltenyi Biotech Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+non-human+primate/pm41604686-80-19-19
    Average 94 stars, based on 1 article reviews
    miltenyi biotech cd1c - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human cd1c bdca1 dendritic cell isolation kit
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Human Cd1c Bdca1 Dendritic Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pm41344082-102-8-16
    Average 94 stars, based on 1 article reviews
    human cd1c bdca1 dendritic cell isolation kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd1c
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+non-human+primate/10__1021_slash_acsomega__5c06105-60-18-24
    Average 94 stars, based on 1 article reviews
    cd1c - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec macs cd1c isolation kit
    cDC2 cell purity and supplementary phenotype analysis. (A) Gating strategy to determine cDC2 purity after isolation from PBMCs. cDC2s were stained for <t>CD1c,</t> CD11c, CD14, and CD20. A first gate is set based on the physical FCS-A/SSC-A parameters followed by selecting on negative cells for CD14 and CD19. cDC2s are then identified as positive cells for CD11c and CD1c. (B) Surface galectin-9 and CCR7 expression in galectin-9 and CCR7-positive cDC2s. Graph shows average ± SEM gMFI of five individual donors. One-way ANOVA followed by Dunnett’s test for multiple comparisons was performed. *P < 0.05; **P < 0.01; ***P < 0.001. gMFI, geometric mean fluorescence intensity.
    Macs Cd1c Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c+bdca+1/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pmc12456409-203-19-25
    Average 94 stars, based on 1 article reviews
    macs cd1c isolation kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: After 2 h of coculture at 37oC, cells were stained to identify DC2s (CD1c-FITC, 1:25, 130-113-301, Miltenyi Biotec) and cDC1s (CD141 PerCP-Cy5.5, 1:25, 344112, BioLegend) prior to analysis using a BD FACSLyricTM.

    Techniques: Ex Vivo, Generated, Expressing, Marker, Fluorescence, MANN-WHITNEY

    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Article Snippet: Alternatively, DCs were enriched by MACS using CD141-Microbeads (130-090-512, Miltenyi Biotec) and CD1c Isolation kit (130-119-475, Miltenyi Biotec) sequentially (see supplementary figure 1C).

    Techniques: Derivative Assay, Generated, Isolation, Expressing, Cell Culture, Marker, Flow Cytometry

    cDC2 cell purity and supplementary phenotype analysis. (A) Gating strategy to determine cDC2 purity after isolation from PBMCs. cDC2s were stained for CD1c, CD11c, CD14, and CD20. A first gate is set based on the physical FCS-A/SSC-A parameters followed by selecting on negative cells for CD14 and CD19. cDC2s are then identified as positive cells for CD11c and CD1c. (B) Surface galectin-9 and CCR7 expression in galectin-9 and CCR7-positive cDC2s. Graph shows average ± SEM gMFI of five individual donors. One-way ANOVA followed by Dunnett’s test for multiple comparisons was performed. *P < 0.05; **P < 0.01; ***P < 0.001. gMFI, geometric mean fluorescence intensity.

    Journal: The Journal of Cell Biology

    Article Title: Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity

    doi: 10.1083/jcb.202404079

    Figure Lengend Snippet: cDC2 cell purity and supplementary phenotype analysis. (A) Gating strategy to determine cDC2 purity after isolation from PBMCs. cDC2s were stained for CD1c, CD11c, CD14, and CD20. A first gate is set based on the physical FCS-A/SSC-A parameters followed by selecting on negative cells for CD14 and CD19. cDC2s are then identified as positive cells for CD11c and CD1c. (B) Surface galectin-9 and CCR7 expression in galectin-9 and CCR7-positive cDC2s. Graph shows average ± SEM gMFI of five individual donors. One-way ANOVA followed by Dunnett’s test for multiple comparisons was performed. *P < 0.05; **P < 0.01; ***P < 0.001. gMFI, geometric mean fluorescence intensity.

    Article Snippet: Human cDC2s were isolated from peripheral blood mononuclear cells derived from healthy individuals (Sanquin, Nijmegen, The Netherlands) using the MACS CD1c + isolation kit (130-119-475; Miltenyi Biotec) according to the manufacturer’s instructions.

    Techniques: Isolation, Staining, Expressing, Fluorescence